4 pharma stocks with up to 20% upside potential
Synopsis
Softening raw material costs, NELM price hike and improved valuations play positive roles.
The pharma sector has faced multiple headwinds in the last few quarters. However, the sector’s outlook appears to be improving as raw material and logistics costs are seeing a softening trend which will help reduce operational costs. Analysts expect price erosion in the US market to reduce to a single digit in 2022-23, which will help support the profitability. Param Desai, Research Analyst, Prabhudas Lilladher, says: “US base business will
- FONT SIZEAbcSmallAbcMediumAbcLarge
Get Unlimited Access to The Economic Times 
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal AdsComment & Engage with ET Prime community Exclusive invites to Virtual Events with Industry Leaders A trusted team of Journalists & Analysts who can best filter signal from noise
